States that are unable to accelerate their efforts to slow Medicaid spending will face long-term budget imbalances, according to a new report from Fitch Ratings.
States that are unable to accelerate their efforts to slow Medicaid spending will face long-term budget imbalances, according to a new report from Fitch Ratings.
CMS has predicted that state and local Medicaid spending growth will average 6.3% annually from 2004 to 2014, partially due to a downshift in federal funding for Medicaid expansion beginning in 2016. This spending growth will still remain below historical trends—from 1990 to 2007 the annual growth averaged 9.3%.
However, despite this slowed growth, Fitch expects it will still outpace revenue growth, forcing states to make challenging budgetary decisions.
“Federal coverage for newly eligible individuals in expansion states will begin a multi-year ramp-down in October 2016 from the current 100% to 90% in federal fiscal 2020 and thereafter. States will need to backfill the federal declines,” according to a press release from Fitch.
Insufficient Data, Disparities Plague Lung Cancer Risk Factor Documentation
September 24th 2023On this episode of Managed Care Cast, we speak with the senior author of a study published in the September 2023 issue of The American Journal of Managed Care® on the importance of adequate and effective lung cancer risk factor documentation to determine a patient's eligibility for screening.
Listen
The Framework for Embracing Gene Therapy in Hemophilia Treatment
September 30th 2023Although gene therapy is anticipated to bring positive changes for people with hemophilia, choosing to receive gene therapy will require empowerment, participation, and shared decision-making, investigators write.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Dato-Dxd Shows Survival Improvements in HR+/HER2– Breast Cancer
September 29th 2023The dual primary end points of overall survival and progression-free survival were encouraging when patients with hormone receptor–positive (HR+), HER2-negative (HER2–) breast cancer were treated with datopotamab deruxtecan.
Read More
2 Clarke Drive
Cranbury, NJ 08512